Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02658279 · ClinicalTrials.gov registry record · NA
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
A NA study of Glioma and Recurrent Malignant Glioma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 27
- Enrollment target
- 16
- Study locations
NCT02658279 is a NA study of Glioma and Recurrent Malignant Glioma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 27 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (87% lower). The trial reports 16 study locations across 8 states.
The verdict
NCT02658279, a NA study of Glioma and Recurrent Malignant Glioma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to test if the study drug called pembrolizumab could control the growth or shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by half, or prevent it from growing for at least 6 months. Pembrolizumab is an antibody that targets the immune system and activates it to stop cancer growth and/or kill cancer cells.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (16)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
New Jersey
- Memorial Sloan Kettering Cancer Center - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
California
- University of California, Los Angeles - Los Angeles
- University of California San Francisco - San Francisco
Florida
- University of Miami - Miami
Ohio
- Cleveland Clinic - Cleveland
Texas
- Md Anderson Cancer Center - Houston
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-01-22 |
| Est. Completion | 2027-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02658279
The ClinicalTrials.gov registry entry for NCT02658279 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (87% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02658279 reports 16 study locations spanning 8 distinct geographic areas - top geographies include New York, Massachusetts, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02658279 about?
NCT02658279 is a clinical study titled "Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype". The purpose of this study is to test if the study drug called pembrolizumab could control the growth or shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by half, or prevent it from growing for at least 6 months. Pembrolizumab ...
What is the current status of trial NCT02658279?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 27 participants. The study started on 2016-01-22. Estimated completion is 2027-01.
What conditions does trial NCT02658279 study?
This clinical trial studies the following conditions: Glioma, Recurrent Malignant Glioma.
What interventions are being tested in trial NCT02658279?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02658279?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02658279 being conducted?
This trial has 16 study locations across California, Florida, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
ASCENT Intervention for Brain Tumor Patients
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.